Guided Therapeutics Re-Establishes Communications With U.S. FDA And Discusses Plan For Refiling For Approval Of The Luviva Advanced Cervical Scan

Published: Jul 18, 2017

Plan includes confirmatory study to boost data previously filed with the Agency

NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has re-opened discussions with the U.S. Food and Drug Administration (FDA) regarding U.S. premarket approval of the Company’s LuViva® Advanced Cervical Scan.

The Company’s decision was prompted by a constructive outcome from the Company’s previous face-to-face meeting with FDA and a perceived more favorable environment for device approvals under the new presidential administration, along with a recent increase in device approvals at the FDA.

In connection with the Company’s plan to re-file for approval of its LuViva® Advanced Cervical Scan, it plans on conducting a new clinical study to confirm previous results already submitted to the FDA. In a telephonic meeting with the FDA, the Company discussed initiating the process by submitting a new study protocol and discussed the possibility of submitting the study data under FDA’s 510(k) de Novo regulations, which, if accepted, could potentially speed up the approval process.

The new clinical study is expected take approximately nine months to complete, after which the Company would submit the data to the FDA. The Company intends on initiating the process by submitting the new study protocol to the FDA within 30 days after funding has been secured. Once final clinical study data has been submitted to the FDA, the FDA will have 180 days to respond with a decision or additional questions.

About LuViva® Advanced Cervical Scan

LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing. LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva® Cervical Guide single-use patient interface and calibration disposable.

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com.

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc.

Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading “Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and subsequent filings.

Contacts

Guided Therapeutics, Inc.
Bill Wells, 770-242-8723

Back to news